David Stewart is a Gastroenterology physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2850 Lewis Ln
Ste 111
Paris, TX 754609383
Telephone
903-785-0025Registry record last updated 28 Mar 2014.
Clinical trials
- Cimzia Versus Mesalamine for Crohn's Recurrence
Sponsor: Milton S. Hershey Medical Center
- Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
Sponsor: National Cancer Institute (NCI)
- Phase I Study of IV DOTAP: Cholesterol-Fus1 in Non-Small-Cell Lung Cancer
Sponsor: M.D. Anderson Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Phathom Pharmaceuticals, Inc.Program year20253 payments
- Novo Nordisk IncProgram year20251 payment
- Phathom Pharmaceuticals, Inc.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
91.2%Proton pump inhibitor28.3%Pantoprazole Sodium44%Omeprazole39%Esomeprazole Magnesium17%Part D<11 patientsOsmotic Laxative26%Gavilyte-G61%Peg-3350 And Electrolytes39%Part D≥88 patients+ 7 more classes in this area
Cancer & immunology
4.1%Interleukin-12 Antagonist2.2%Stelara100%Part D<11 patientsNucleoside Metabolic Inhibitor2%Mercaptopurine100%Part D<11 patientsNervous system
2.3%Tricyclic Antidepressant2.3%Amitriptyline Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Josep M. Llovet
Institució Catalana de Recerca i Estudis Avançats
Joseph J.�Y. Sung
Nanyang Technological University
Neeraj Bhala
The Royal Melbourne Hospital
Jordi Bruix
Hospital Clínic de Barcelona
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”